<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01126229</url>
  </required_header>
  <id_info>
    <org_study_id>238-2009</org_study_id>
    <nct_id>NCT01126229</nct_id>
  </id_info>
  <brief_title>Resveratrol for Improved Performance in the Elderly</brief_title>
  <acronym>RIPE</acronym>
  <official_title>A Pilot Study of Resveratrol Supplementation for Memory and Physical Performance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florida</source>
  <brief_summary>
    <textblock>
      The investigators aim to conduct a randomized placebo controlled pilot study to determine&#xD;
      whether resveratrol, a dietary ingredient, supplementation is safe and improves memory and&#xD;
      physical performance in older adults. Loss in memory and physical performance is a frequent&#xD;
      complaint in older adults and a growing public health issue. Additionally, later adulthood is&#xD;
      associated with a normative decline in both working and primary memory as well as domains&#xD;
      including attention, speed of processing and executive function. Resveratrol is safely&#xD;
      tolerated in pre-clinical models and in dose-escalation human studies. It also has&#xD;
      demonstrated beneficial effects on memory and performance in pre-clinical models. Therefore,&#xD;
      this study will take the next step in understanding the longer-term safety (3 months) and&#xD;
      efficacy of resveratrol supplementation on age-related health conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enrolled participants will complete psychological questionnaires and a multi-measure&#xD;
      cognitive test battery, physical function, as well as provide blood samples, to determine&#xD;
      blood chemistry. These will include complete blood count and complete metabolic count [(Na,&#xD;
      K, Cl, CO2, BUN, Creatinine, Glucose, Total Protein, Albumin, Calcium, Phosphorous, Aspartate&#xD;
      Aminotransferase (AST), Alkaline Phos, Total Bilirubin, and Alanine Amino Transferase (ALT)]&#xD;
      and any others deemed necessary by the study physician. They will return to the laboratory to&#xD;
      perform a muscular endurance test and MRI evaluation at the Brain Institute. Eligible&#xD;
      participants will be randomly assigned with equal probability to either receive resveratrol&#xD;
      (300 mg/d or 1000 mg/d) or placebo for twelve weeks. Immediately following completion of the&#xD;
      MRI, participants will be given a month's supply of resveratrol or placebo. All participants&#xD;
      will be closely monitored for safety and toxicity during the first 10 days (range 8-12 days&#xD;
      are acceptable) of the trial. During this initial evaluation period, blood chemistries&#xD;
      (complete metabolic profiles) will be evaluated every 3 (range 1-2 days are acceptable) days.&#xD;
      Following one month, participants will be asked to return to clinic. At their monthly visits,&#xD;
      memory tests, blood samples will be collected to monitor cognitive adaptations and ensure&#xD;
      that no adverse changes have occurred. Participants' compliance with the supplementation&#xD;
      regimen will also be checked through pill counts, and participants will be given a month's&#xD;
      supply of product at each of their monthly visits. After 12 weeks of taking either&#xD;
      resveratrol or a placebo on a daily basis, participants will complete a final test battery,&#xD;
      an MRI scan, a blood draw collection. A follow-up evaluation will be provided at 10 and 30&#xD;
      days following completion of the final post-treatment assessment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Outcomes</measure>
    <time_frame>24 months</time_frame>
    <description>CBC, Complete Metabolic Panel, Toxicity according to NCI criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive Outcomes</measure>
    <time_frame>24 months</time_frame>
    <description>Executive function measured by N-back and Controlled Oral Word Association test, Processing Speed measuring by Trails A &amp; B, Memory Function measured by word recall.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Outcomes</measure>
    <time_frame>24 months</time_frame>
    <description>Physical function measured by performance on the 400 meter walk test, physical activity levels as measured by accelerometer.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Memory</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dietary Supplement: placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>300 mg/d Resveratrol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dietary Supplement: 300 mg/d Resveratrol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1000 mg/d Resveratrol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dietary Supplement: 1000 mg/d Resveratrol</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 capsules of placebo daily for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose Resveratrol</intervention_name>
    <description>2 capsules daily for 12 weeks containing 300 mg/d (combined) of resveratrol active ingredient</description>
    <arm_group_label>300 mg/d Resveratrol</arm_group_label>
    <other_name>ReserveAge</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose Resveratrol</intervention_name>
    <description>2 capsules daily for 12 weeks containing 1000 mg/d (combined) of resveratrol active ingredient</description>
    <arm_group_label>1000 mg/d Resveratrol</arm_group_label>
    <other_name>ReserveAge</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women aged 65-100 years&#xD;
&#xD;
          -  Body mass index &gt; = 25 and &lt; = 35&#xD;
&#xD;
          -  Willing and able to participate in all aspects of the study&#xD;
&#xD;
          -  Willing to be randomized to either treatment group&#xD;
&#xD;
          -  Sedentary to moderately active lifestyle (&lt;120 min aerobic activity/week)&#xD;
&#xD;
          -  Report of ability to walk one mile&#xD;
&#xD;
          -  MMSE &gt; 24&#xD;
&#xD;
          -  Non-smoking&#xD;
&#xD;
          -  Telephone Interview for cognitive status (TICS)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active treatment for cancer, stroke (&lt; 6 mo), peripheral vascular disease, coronary&#xD;
             artery disease (myocardial infarction &lt;6 mo), state III, IV Congestive Heart Failure,&#xD;
             valvular heart disease, major psychiatric disease, severe anemia, liver or renal&#xD;
             disease, diabetes, severe osteoarthritis, blindness or deafness, fracture in upper or&#xD;
             lower extremity within the last 6 months, upper or lower extremity amputation,&#xD;
             anticoagulant therapy (aspirin use is permitted), parkinsons disease&#xD;
&#xD;
          -  Failure to give consent&#xD;
&#xD;
          -  Anabolic medications (growth hormone or testosterone)&#xD;
&#xD;
          -  High amounts of physical activity (i.e. running, bicycling etc) &gt; 120 min/week.&#xD;
&#xD;
          -  Dementing illness&#xD;
&#xD;
          -  Excessive alcohol use (&gt;2 drinks per day)&#xD;
&#xD;
          -  Resting heart rate &gt; 120 bpm&#xD;
&#xD;
          -  Systolic blood pressure &gt; 180 mmHg&#xD;
&#xD;
          -  Diastolic blood pressure &gt; 100 mmHg&#xD;
&#xD;
          -  Dietary supplementation of grape seed extract or ginko biloba&#xD;
&#xD;
          -  History of significant head injury&#xD;
&#xD;
          -  Vision or hearing impairment&#xD;
&#xD;
          -  Anticholinesterase inhibitor (such as Aricept)&#xD;
&#xD;
          -  Contraindications to MRI (e.g. cardiac pacemaker, implanted cardiac defibrillator,&#xD;
             aneurysm clip, claustrophobia, etc.)&#xD;
&#xD;
          -  Consumption of red wine/dealcoholized red wine/red or purple grape juice more than&#xD;
             once weekly; consumption of any dietary supplements containing resveratrol, quercetin,&#xD;
             or P. cuspidatum in the previous 90 days;&#xD;
&#xD;
          -  Subject is participating in another clinical trial or has received an investigational&#xD;
             product within 30 days prior to screening/enrollment&#xD;
&#xD;
          -  Current Use of Antidepressant Medications&#xD;
&#xD;
          -  CES-D Score &gt; 20&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Todd M. Manini, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida, Aging and Geriatric Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen M Manini, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida, Aging and Geriatric Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida, Aging and Geriatric Research</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>May 17, 2010</study_first_submitted>
  <study_first_submitted_qc>May 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2010</study_first_posted>
  <last_update_submitted>December 10, 2013</last_update_submitted>
  <last_update_submitted_qc>December 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Resveratrol</keyword>
  <keyword>Grape</keyword>
  <keyword>Aging</keyword>
  <keyword>functional MRI (fMRI)</keyword>
  <keyword>Anti-Aging therapeutic</keyword>
  <keyword>Oxidative Stress</keyword>
  <keyword>Functional Performance</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Resveratrol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

